A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
|Articles|December 1, 1996
Supplements and Featured Publications
- Creating an Optimal Strategy for Lipid Management
- Volume 2
- Issue 11 Suppl
Case Study D
Advertisement
Articles in this issue
almost 30 years ago
Dialogue: Implementation of Guidelines in a Managed Care Settingalmost 30 years ago
Dialogue: The Lipid-Lowering Formularyalmost 30 years ago
Case Study Balmost 30 years ago
Case Study Calmost 30 years ago
Goals and Objectivesalmost 30 years ago
Introduction: Creating an Optimal Strategy for Lipid Managementalmost 30 years ago
Recent Clinical Trials and Aggressive Management of Dyslipidemic Patientsalmost 30 years ago
Epidemiologic Studies of Diet and Drug Therapy to Reach Target LDL-C Levelsalmost 30 years ago
Implementation of Guidelines in a Managed Care Settingalmost 30 years ago
The Lipid-Lowering FormularyAdvertisement
Related to this article
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5